• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Non-small-cell lung"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-20 of 20

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC-ECSG phase II clinical study 

      Gamucci, T.; Paridaens, R.; Heinrich, B.; Schellens, J. H. M.; Pavlidis, Nicholas; Verweij, J.; Sessa, Cristiana; Kaye, Stanley B.; Roelvink, M.; Wanders, J.; Hanauske, A. R. (2000)
      Background: GI147211 is a water-soluble synthetic analogue of camptothecin showing promising in vivo and in vitro antitumor activity and an acceptable toxicity profile. Patients and methods: Between April 1995 and November ...

    • Article  

      Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features 

      Pentheroudakis, George; Kostadima, Lida; Fountzilas, George; Kalogera-Fountzila, Anna; Klouvas, G. D.; Kalofonos, H. P.; Pavlidis, Nicholas (2004)
      Introduction: Patients with cavitating squamous lung carcinoma (cSLC) are believed to harbor aggressive, chemoresistant disease with distinct features and fare poorly. We retrospectively analyzed radiologic, histologic, ...

    • Article  

      Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study 

      Kosmidis, Paraskevas A.; Fountzilas, George; Baka, S.; Samantas, E.; Dimopoulos, M. A.; Gogas, H.; Skarlos, Dimosthenis V.; Papacostas, P.; Boukovinas, I.; Bakoyiannis, Chris; Pantelakos, P.; Athanassiou, E.; Misailidou, D.; Tsekeris, P.; Pavlidis, Nicholas (2007)
      Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent ...

    • Article  

      Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A phase III randomized study. Preliminary results 

      Kosmidis, Paraskevas A.; Mylonakis, N.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Samantas, E.; Dimitriadis, K.; Kalofonos, H. P.; Tsavdaridis, D.; Skarlos, Dimosthenis V. (2000)
      Gemcitabine plus paclitaxel and paclitaxel plus carboplatin are active and well tolerated in patients with advanced non-small cell lung cancer, showing similar rates of response and survival. The Hellenic Cooperative ...

    • Article  

      Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): Report of a case and review of the literature 

      Voulgaris, E.; Pentheroudakis, George; Vassou, A.; Pavlidis, Nicholas (2009)
      The clinical manifestation of disseminated intravascular coagulation (DIC) as paraneoplastic phenomenon is common in patients with lung cancer (especially in those with non small cell lung cancer).Surprisingly, only few ...

    • Article  

      Docetaxel (Taxotere™) is active in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG) 

      Cerny, T.; Kaplan, S.; Pavlidis, Nicholas; Schöffski, P.; Epelbaum, R.; Meerbeek, J. van; Wanders, J.; Franklin, H. R.; Kaye, Stanley B. (1994)
      In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxotere). Six patients were ineligible; of ...

    • Article  

      ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC) 

      Felip, E.; Stahel, R. A.; Pavlidis, Nicholas (2005)

    • Article  

      Five tumor markers in lung cancer: Significance of total and>-Bound sialic acid 

      Kakari, S.; Stringou, E.; Toumbis, M.; Ferderigos, A. S.; Poulaki, E.; Chondros, K.; Dema, A.; Kotsovoulou, V.; Pavlidis, Nicholas (1991)
      Total sialic acid (TSA) and > sialic acid (LSA) were evaluated in comparison to carcinoembryonic antigen (CEA) and ferritin and neuron specific enolase (NSE) in 152 untreated patients with primary lung cancer, 107 benign ...

    • Article  

      Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group study (HeCOG) 

      Nikolaides, C.; Klouvas, G. D.; Fountzilas, George; Athanasiades, A.; Skarlos, Dimosthenis V.; Samantas, E.; Kosmidis, Paraskevas A.; Mylonakis, N.; Pavlidis, Nicholas (1997)
      This is a continuation of a HeCOG previous trial utilizing carboplatin and vindesine in conventional doses as a non-toxic regimen provided easily on an outpatient basis in NSCLC. In the present study we investigated whether ...

    • Article  

      Multicentre phase II pharmacological evaluation of rhizoxin 

      McLeod, H. L.; Murray, L. S.; Wanders, J.; Setanoians, A.; Graham, M. A.; Pavlidis, Nicholas; Heinrich, B.; Huinink, W. W. Ten Bokkel; Wagener, D. J. Th; Aamdal, S.; Verweij, J. (1996)
      Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines and xenograft models. ...

    • Article  

      Non-small cell lung cancer in the young: A retrospective analysis of diagnosis, management and outcome data 

      Mauri, D.; Pentheroudakis, George; Bafaloukos, Dimitrios; Pectasides, Dimitrios; Samantas, E.; Efstathiou, E.; Kalofonos, H. P.; Syrigos, K.; Klouvas, G. D.; Papakostas, P.; Kosmidis, Paraskevas A.; Fountzilas, George; Pavlidis, Nicholas (2006)
      Background: Non-small cell lung cancer (NSCLC) in young patients is uncommon and is thought to constitute a distinct oncological entity with characteristic clinicopathological patterns. Since the reported data are scant ...

    • Article  

      Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial 

      Kosmidis, Paraskevas A.; Mylonakis, N.; Skarlos, Dimosthenis V.; Samantas, E.; Dimopoulos, M. A.; Papadimitriou, C.; Kalofonos, H. P.; Pavlidis, Nicholas; Nikolaides, C.; Papaconstantinou, C.; Fountzilas, George (2000)
      Purpose: The combination of paclitaxel and carboplatin has become a widely used regimen in NSCLC due to phase II reports of moderate toxicity, reasonable activity and easy outpatient administration. Purpose of our present ...

    • Article  

      Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study. 

      Kosmidis, Paraskevas A.; Mylonakis, N.; Fountzilas, George; Samantas, E.; Athanasiades, A.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (1997)
      A recent phase II study by our group documented a response rate of 27% with the combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 plus carboplatin dosed to a target area under the ...

    • Article  

      Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study 

      Kosmidis, Paraskevas A.; Mylonakis, N.; Fountzilas, George; Samantas, E.; Athanasiades, A.; Andreopoulou, E.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (1997)
      Background: Based on the high activity of single-agent paclitaxel and the superior one-year survival rates of patients with non-small-cell lung cancer (NSCLC) treated with carboplatin, a phase II trial was initiated using ...

    • Article  

      Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer 

      Verweij, J.; Wanders, J.; Nielsen, A. L.; Pavlidis, Nicholas; Calabresi, F.; Huinink, W. T. B.; Bruntsch, U.; Piccart, M.; Franklin, H. R.; Kaye, Stanley B. (1994)
      Purpose: To test the antitumor activity of Elsamitrucin in metastatic cancer of the breast, colon and rectum, non-small cell lung and ovary. Patients and methods: Eligibility required histologically proven cancer. Patients ...

    • Article  

      A Phase II trial of carboplatin and vindesine in patients with non-small cell lung cancer. A Hellenic Cooperative Oncology Group study 

      Pavlidis, Nicholas; Klouvas, G. D.; Nikolaides, C.; Karantanas, A. H.; Beer, M.; Fountzilas, George (1993)
      In an effort to investigate a regimen less toxic and more convenient than cisplatin combinations, 50 patients with non-small cell lung cancer (NSCLC) were treated in a Phase II study with carboplatin and vindesine. Carboplatin ...

    • Article  

      Positive urinary cytology in patients with lung cancer in the absence of obvious urine tract metastases 

      Voulgaris, E.; Pentheroudakis, George; Pappa, L.; Bafa, M.; Goussia, Anna; Dalezis, P.; Tsombanidou, C.; Geromichalos, G.; Papageorgiou, A.; Koutsilieris, M.; Malamou-Mitsi, Vassiliki D.; Pavlidis, Nicholas (2011)
      Purpose: To study the phenomenon of positive urine cytology in patients with lung cancer in the absence of obvious urothelial metastases. Patients and methods: 150 patients with small (SCLC) and non-small cell lung cancer ...

    • Article  

      Single agent activity of rhizoxin in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group 

      Kaplan, S.; Hanauske, A. R.; Pavlidis, Nicholas; Bruntsch, U.; Velde, A. Te; Wanders, J.; Heinrich, B.; Verweij, J. (1996)
      In a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31 chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel tubulin-binding agent. The drug was ...

    • Article  

      The value of neuroendocrine markers in non-small cell lung cancer: a comparative immunohistopathologic study 

      Kiriakogiani-Psaropoulou, P.; Malamou-Mitsi, Vassiliki D.; Martinopoulou, U.; Legaki, S.; Tamvakis, N.; Vrettou, E.; Fountzilas, George; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (1994)
      In order to estimate the value of immunohistochemical identification of neuroendocrine (NE) differentiation markers in non-small cell lung carcinomas (NSCLCs), we investigated the expression of five neuroendocrine and ...

    • Article  

      Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2 

      Kosmidis, Paraskevas A.; Syrigos, K.; Kalofonos, H. P.; Dimopoulos, M. A.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Boukovinas, I.; Bafaloukos, Dimitrios; Pectasides, Dimitrios; Bacoyiannis, Charalambos; Fountzilas, George (2012)
      Aim: The purpose of this study was to compare two single agents paclitaxel (intravenous) versus vinorelbine (oral) in non-small cell lung cancer (NSCLC) patients with performance status (PS):2. Patients and Methods: The ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD